DNLI - デナリ・セラピュ―ティクス (Denali Therapeutics Inc.) デナリ・セラピュ―ティクス

 DNLIのチャート


 DNLIの企業情報

symbol DNLI
会社名 Denali Therapeutics Inc (デナリ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デナリ・セラピューティクス(Denali Therapeutics Inc.)はバイオテクノロジー企業である。同社は、アルツハイマー病、パーキンソン病、筋萎縮性側索硬化症(ALS)などの神経変性疾患患者の治療法の発見と開発に従事する。同社は、遺伝的原因及び神経変性疾患の根底にある生物学的プロセスに関する科学的な洞察に基づいて、治療薬の多様なポートフォリオを開発する。同社は、脱遺伝子遺伝子(変異した場合に神経変性疾患を引き起こす遺伝子)、欠陥細胞内輸送、グリア機能障害および軸索変性を含む、神経変性のトリガーまたはエフェクターとして関与する約4つの特異的経路を選択した。同社の開発プログラムには、リソソーム機能経路、グリア細胞生物学的経路、および細胞恒常性経路が含まれる。同社の製品パイプラインには、DNL201、DNL 151、ATV:aSyn、ETV:IDS、DNL747、ATV:TREM2などの薬物候補が含まれる。   デナリ・セラピュ―ティクスは米国のバイオ医薬品会社。アルツハイマ―病、パ―キンソン病、筋萎縮性側索硬化症(ALS)などに代表される神経変性疾患に対する治療薬の発見・開発に従事。疾患の原因やリスク要因に直接対処することを目指し、6つの異なるプログラムで臨床開発及び臨床前開発に取り組む。本社はカリフォルニア州サウス・サンフランシスコ。   Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.
本社所在地 151 Oyster Point Blvd. 2nd Floor South San Francisco CA 94080 USA
代表者氏名 Marc Tessier-Lavignec マルクテッシーエ - ラヴィーニェック
代表者役職名 Chairman of the Board Co-Founder
電話番号 +1 650-866-8548
設立年月日 41548
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 130人
url www.denalitherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/dnli
adr_tso
EBITDA EBITDA(百万ドル) -124.66400
終値(lastsale) 18.34
時価総額(marketcap) 1738762415.74
時価総額 時価総額(百万ドル) 1690.411
売上高 売上高(百万ドル) 2.28900
企業価値(EV) 企業価値(EV)(百万ドル) 1317.82
当期純利益 当期純利益(百万ドル) -123.13300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Denali Therapeutics Inc revenues increased from $0K to $2.3M. Net loss increased 80% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense - Balanci increase of 89% to $68.7M (expense) Stock-based Compensation in R&D increase from $1.2M to $4.3M (expense) Selling.

 DNLIのテクニカル分析


 DNLIのニュース

   Denali Therapeutics (DNLI) Presents At Goldman Sachs 42nd Annual Global Healthcare Conference - Slideshow  2021/06/10 19:11:20 Seeking Alpha
   Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis  2021/06/08 15:09:35 ETF Daily News
Regarding the trend, note that the strongest trend exists on the 50 day timeframe. The post Denali Therapeutics Inc (DNLI): Price Now Near $70.67; Daily Chart Shows Downtrend on 100 Day Basis appeared first on ETF Daily News .
   Denali Therapeutics (DNLI ) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow  2021/06/03 00:19:31 Seeking Alpha
   Denali Therapeutics (DNLI) Presents At UBS 2021 Global Healthcare Virtual Conference - Slideshow  2021/05/25 19:18:34 Seeking Alpha
   Tao Capital Management LP Buys Denali Therapeutics Inc, Sells Tesla Inc, Uber Technologies Inc, ...  2021/05/18 18:38:33 GuruFocus
Related Stocks: DNLI ,
   Eli Lilly bolsters neuro, immunology pipeline via multi-drug alliance with Rigel - MedCity News  2021/02/18 17:28:37 MedCity News
Eli Lilly is paying $125 million up front to team up with Rigel Pharmaceuticals on drugs that block a signaling protein involved in inflammation. With the alliance, Lilly joins Sanofi and Denali Therapeutics in the pursuit of drugs that block this protein.
   STAT+: Experts encouraged by Denali’s early results in study of Hunter syndrome drug  2021/02/12 12:29:32 STAT News
A preliminary study of a medicine developed by Denali Therapeutics to treat Hunter syndrome, a rare genetic disease, has left outside experts encouraged by its potential.
   Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells 1,470 Shares of Stock  2021/02/12 02:26:58 Watchlist News
Denali Therapeutics Inc. (NASDAQ:DNLI) insider Carole Ho sold 1,470 shares of the business’s stock in a transaction dated Tuesday, February 9th. The stock was sold at an average price of $74.68, for a total value of $109,779.60. Following the sale, the insider now owns 1,476 shares in the company, valued at approximately $110,227.68. The transaction […]
   Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors  2021/01/11 13:30:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad…
   Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration  2021/01/08 13:30:00 GlobeNewswire
Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on…
   Biogen reports 11.16% passive stake in Denali Therapeutics (NASDAQ:DNLI)  2020/09/28 20:37:54 Seeking Alpha
Biogen purchases ~13.3M shares of Denali Therapeutics (NASDAQ:DNLI) on September 22. This represents 11.16% of total shares outstanding. The stake does not
   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO  2020/09/16 12:00:28 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.
   MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics  2020/08/26 09:00:00 PR Newswire
FOSTER CITY, California, Aug. 26, 2020 /PRNewswire/ -- MedGenome, a leading genomic diagnostics, research and data company based in Foster City, CA and Bangalore, India, today announced that it has formed a strategic discovery collaboration focused on novel discoveries in Parkinson's…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デナリ・セラピュ―ティクス DNLI Denali Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)